@article{f52fac16f62442d5874a92499b82f616,
title = "Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials",
abstract = "Background The standard of care for operable, stage I, non-small-cell lung cancer (NSCLC) is lobectomy with mediastinal lymph node dissection or sampling. Stereotactic ablative radiotherapy (SABR) for inoperable stage I NSCLC has shown promising results, but two independent, randomised, phase 3 trials of SABR in patients with operable stage I NSCLC (STARS and ROSEL) closed early due to slow accrual. We aimed to assess overall survival for SABR versus surgery by pooling data from these trials. Methods Eligible patients in the STARS and ROSEL studies were those with clinical T1-2a (",
author = "Chang, {Joe Y.} and Suresh Senan and Paul, {Marinus A.} and Mehran, {Reza J.} and Louie, {Alexander V.} and Peter Balter and Groen, {Harry J. M.} and McRae, {Stephen E.} and Joachim Widder and Lei Feng and {van den Borne}, {Ben E. E. M.} and Munsell, {Mark F.} and Coen Hurkmans and Berry, {Donald A.} and {van Werkhoven}, Erik and Kresl, {John J.} and Anne-Marie Dingemans and Omar Dawood and Haasbeek, {Cornelis J. A.} and Carpenter, {Larry S.} and {De Jaeger}, Katrien and Ritsuko Komaki and Slotman, {Ben J.} and Smit, {Egbert F.} and Roth, {Jack A.}",
year = "2015",
month = jun,
doi = "10.1016/S1470-2045(15)70168-3",
language = "English",
volume = "16",
pages = "630--637",
journal = "Lancet oncology",
issn = "1470-2045",
publisher = "Elsevier Ltd",
number = "6",
}